Skip to main content

IDEXX Laboratories, Inc. (IDXX) Stock Analysis

Recovery setup

Buy WaitVALUE-TRAP 1/5Moderate Confidence

Healthcare · Diagnostics & Research

Wait for pullback to $533.06. BUY gates pass at $553.58, but concentration risk — Supplier: Ortho-Clinical Diagnostics and earnings estimates trending DOWN argue for a more patient entry. Engine's entry $533.06 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.

IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments, reference laboratory testing, and practice management software—primarily for companion animal veterinary practices worldwide. R&D was $251.2M (5.8% of revenue) in... Read more

$553.58+15.6% A.UpsideScore 5.6/10#13 of 26 Diagnostics & Research
QualityF-score8 / 9FCF yield1.83%
Entry $533.06(Atr Pullback Sticky)Stop $492.98Target $616.95(analyst − 13%)A.R:R 1.6:1Setup A.R:R 3.3:1
Analyst target$709.14+28.1%14 analysts
$616.95our TP
$553.58price
$709.14mean
$470
$805

Wait for pullback to $533.06. BUY gates pass at $553.58, but concentration risk — Supplier: Ortho-Clinical Diagnostics and earnings estimates trending DOWN argue for a more patient entry. Engine's entry $533.06 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 47. Wide-moat business. Accumulate on weakness. Score 5.6/10, moderate confidence.

Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

Val3.5Qual8.4Grw5.8Mom5.9Sent6.8Ins3.9Peer4.1Tech4.9Risk6.05.6OVERALL

Recent Developments — IDEXX Laboratories, Inc.

Latest news

Generated 2026-05-20T21:56:22Z.

Thesis

Rewards
V7 flight-to-quality bonus: +0.5 (Q=8.4 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Risks
Concentration risk — Supplier: Ortho-Clinical Diagnostics
Earnings estimates trending DOWN
Expensive valuation

Key Metrics

P/E (TTM)40.2
P/E (Fwd)33.1
Mkt Cap$43.1B
EV/EBITDA28.5
Profit Mgn24.6%
ROE72.9%
Rev Growth14.3%
Beta1.57
DividendNone
Rating analysts23

Quality Signals

Piotroski F8/9MoatWideCompounder✓

Options Flow

P/C0.89neutral
IV35%normal
Max Pain$430-22.3% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSupplierOrtho-Clinical Diagnostics
    10-K Item 1: 'We are obligated to purchase all of our requirements for our current menu of Catalyst chemistry slides from Ortho to the extent Ortho is able to supply those requirements'

Material Events(8-K, last 90d)

  • 2026-03-26Item 5.02MEDIUM
    EVP Nimrata Hunt mutually agreed to cease as EVP Global Strategy and Commercial effective April 13, 2026, with advisory services through July 13, 2026. No named replacement for the role; no disagreement cited.
    SEC filing →
  • 2026-02-13Item 5.02LOW
    Director M. Anne Szostak notified IDEXX of her intention to retire from the Board effective immediately following the 2026 Annual Meeting (May 12, 2026). No disagreement with company cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ev Ebitda
0.0
Pe
3.0
Forward Pe
3.4
Peg Ratio
3.5
Ps
3.7
Analyst Target
6.0
Forward P/E: 33.1xPEG: 3.39
GatesMomentum 5.9>=5.5A.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 75d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
47 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $523.38Resistance $585.12

Price Targets

$493
$533
$617
A.Upside+11.4%
A.R:R1.6:1
Setup A.R:R (at entry)3.3:1

Position Sizing

ConvictionHigh conviction
Suggested %0.8%
Max %1.7%
RegimeRisk-Off

Analyst Consensus

Analysts23
Consensus4.0/5
Avg Target$709

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-03 (75d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is IDXX stock a buy right now?

Wait for pullback to $533.06. BUY gates pass at $553.58, but concentration risk — Supplier: Ortho-Clinical Diagnostics and earnings estimates trending DOWN argue for a more patient entry. Engine's entry $533.06 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 47. Wide-moat business. Accumulate on weakness. Target $616.95 (+11.4%), stop $492.98 (−12.3%), Setup A.R:R 3.3:1. Score 5.6/10, moderate confidence.

What is the IDXX stock price target?

Take-profit target: $616.95 (+15.6% upside). Target $616.95 (+11.4%), stop $492.98 (−12.3%), Setup A.R:R 3.3:1. Stop-loss: $492.98.

What are the risks of investing in IDXX?

Concentration risk — Supplier: Ortho-Clinical Diagnostics; Earnings estimates trending DOWN; Expensive valuation.

Is IDXX overvalued or undervalued?

IDEXX Laboratories, Inc. trades at a P/E of 40.2 (forward 33.1). TrendMatrix value score: 3.5/10. Verdict: Buy (Wait for Entry).

What do analysts say about IDXX?

23 analysts cover IDXX with a consensus score of 4.0/5. Average price target: $709.

What does IDEXX Laboratories, Inc. do?IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments,...

IDEXX Laboratories develops and manufactures veterinary diagnostic products and services—point-of-care instruments, reference laboratory testing, and practice management software—primarily for companion animal veterinary practices worldwide. R&D was $251.2M (5.8% of revenue) in 2025, with highly recurring revenue from consumables and subscriptions sold direct to veterinarians in the U.S. and internationally.

Related stocks: MEDP (Medpace Holdings, Inc.) · WAT (Waters Corporation) · SHC (Sotera Health Company) · GH (Guardant Health, Inc.) · DGX (Quest Diagnostics Incorporated)